New cancer Drug's interactions under the microscope
NCT ID NCT07388511
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This completed Phase 1 study looked at how a new drug called elenestinib affects the way the body processes midazolam (a sedative) and a common birth control pill. Twenty healthy adult women took these drugs with and without elenestinib, and researchers measured drug levels in their blood. The goal was to see if elenestinib changes how these other drugs work, which is important for future safe use.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- elenestinib
- What this could lead to
- If successful, this study will help doctors understand how elenestinib interacts with other drugs, leading to safer dosing guidelines.
- What could go wrong
- This is a very early, small study in healthy volunteers, not patients. Results may not predict effects in people with the disease or with other medications.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY PARTICIPANTS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Celerion, Inc
Tempe, Arizona, 85282, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a common antifungal change how an experimental drug acts?
- Can a new injection help tackle obesity? a safety trial begins
- Will a new pill formula absorb the same? a trial puts it to the test
- Can a new drug tame Alzheimer's? early trial aims to find out
- Could sitting too much alter your nervous system?
- Could a cancer drug alter Metformin's effects? a trial investigates